 Glucokinase GK, also called hexokinase IV or D can phosphosphorylate glucose to glucose-6-phosphate G-6-P in pancreatic β-cells and liver cells, which represents the first step of glucose metabolism. GK also acts as a glucose sensor and exerts a key role in maintaining glucose homeostasis. HMS5552 is a 4th-generation GK agonist or activator GKA, which was originally licensed from Roche and subsequently developed by Hua Medicine. HMS5552 has been shown to activate GK in pancreatic beta cells, liver and intestinal epithelial cells. It regulates systemic blood glucose through a variety of mechanisms including directly enhancing insulin release pancreas, inhibiting production of endogenous glucose liver and by indirectly promoting GLP-1 release enteroendocrine L-cells. 